Home / Health / New HIV Drug Combo Offers Hope for Resistant Virus
New HIV Drug Combo Offers Hope for Resistant Virus
9 Oct
Summary
- A new long-acting drug combination can control HIV resistant to other treatments.
- Lenacapavir swapped for rilpivirine maintained undetectable HIV for nearly two years.
- This breakthrough offers a viable option for patients struggling with daily HIV pills.
A groundbreaking long-acting drug combination has emerged as a potent solution for HIV patients battling drug-resistant strains. Researchers reported on October 8, 2026, that swapping lenacapavir for rilpivirine in the cabotegravir/rilpivirine regimen successfully restored HIV control in a small patient group.
This innovative approach specifically targets patients whose virus has developed resistance, a limitation for the standard long-acting injectable treatment. The lenacapavir/cabotegravir combination works by attacking HIV through a different mechanism, disrupting the virus's protective shell.
In a study involving 46 patients at UCSF's Ward 86 HIV Clinic, the new combination brought detectable HIV under control within 13 weeks. Crucially, after nearly two years, all participants maintained undetectable HIV viral loads, demonstrating the regimen's sustained efficacy.
This finding offers critical evidence for clinicians, potentially increasing their confidence in using this combination. The study's funding came from a federal grant, ensuring its independence from pharmaceutical influence.
